The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.
In compliance with applicable State regulatory authorities, COVID-19 vaccination is mandatory for all MSK staff. Staff are considered fully vaccinated upon completion of a primary vaccination series for COVID-19 (i.e., one dose of a single dose vaccine or a final dose of a multi-dose vaccine series). Exceptions from the COVID-19 vaccine requirement are permitted for those who request and receive an approved medical or fully remote exemption. Requests for medical exemption can take up to two weeks to review. Vaccination or an approved medical exemption is required to start work.
Note: Individuals are eligible to receive a COVID-19 booster two months after completion of a primary vaccination series for COVID-19. Because vaccine-induced immunity can wane over time, MSK continues to strongly urge all staff to get a COVID-19 booster as soon as they become eligible to maintain their protective immunity for a longer period.
The Emily Cheng laboratory at the Human Oncology & Pathogenesis Program is seeking highly motivated and successful individuals to study the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy (Science 330: 1390-1393; Cancer Cell 39: 1245-1261; Nature Cancer 3: 188-202; Molecular Cell 36: 487-499; Nature Cell Biology 8: 1348-1358; Nature Cell Biology 17: 1270-1281; Nature Communications 7: 13131;). The research projects are aimed at delineating aberrant survival/death signaling pathways in cancer, studying epigenetic regulation of cell death and epigenetic mechanisms of resistance to targeted therapy, interrogating the impact of different types of cell death (apoptosis, BAX/BAK-dependent immunogenic cell death, pyroptosis, necroptosis, ferroptosis, etc.) on tumor-immune crosstalk and immunotherapy, and identifying therapeutic strategies that trigger potent immunogenic cell death in cancer.
The ideal candidate should have:
If you have any questions about this job opportunity, please contact:
Emily Cheng, M.D., Ph.D.
Salary: $55,439 – $100,940
MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision.
Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment.
Software Powered by iCIMS
www.icims.com